



MARK B. WILSON
PARTNER
MBWILSON@FULBRIGHT.COM

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM


DIRECT DIAL: (512) 536-3035
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

November 30, 2004

CERTIFICATE OF MAILING
37 C.F.R 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 30, 2004
Date


Mark B. Wilson

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/786,875 entitled "IMPROVED NUCLEASE INHIBITOR COCKTAIL" – Gary J. Latham et al.*
Our reference: AMBI:089US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references A1-A2, B1, and C1-C27.


No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:089US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Mark B. Wilson
Reg. No. 37,259

MBW/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Gary J. Latham *et al.*

Serial No.: 10/786,875

Filed: February 25, 2004

For: IMPROVED NUCLEASE INHIBITOR
COCKTAIL

Group Art Unit: 1634


Examiner: Unknown

Atty. Dkt. No.: AMBI:089US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

November 30, 2004
Date


Mark B. Wilson

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be


an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/AMBI:089US.

This application is related by subject matter to co-pending U.S. application number 09/669,301 filed September 25, 2000 now issued as 6,664,379, number 10/675,860 filed September 30, 2003, and provisional application number 60/547,721 filed February 25, 2004.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson
Reg. No. 37,259
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: November 30, 2004

Form PTO-1449 (modified)

Atty. Docket No.
AMBI:089USSerial No.
10/786,875

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant
Gary J. Latham *et al.*Filing Date:
February 25, 2004Group:
1634U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 1*Other Art
See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	6,110,968	8/29/00	Bucala <i>et al.</i>	514	482	11/10/98
	A2	6,664,379	12/16/03	Kudlicki <i>et al.</i>	530	387.9	9/25/00

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 2004/005663	1/15/04	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Allewell and Sama, "The effect of ammonium sulfate on the activity of ribonuclease a," <i>Biochem. Biophys. ACTA</i> , 341:484-488, 1974.
	C2	Blackburn <i>et al.</i> , "Ribonuclease inhibitor from human placenta: interaction with derivatives of ribonuclease A," <i>J. Biol. Chem.</i> 252:12488-12493, 1977.
	C3	Blumberg, "Creating a ribonuclease-free environment," <i>Methods Enzymol.</i> 152:20-24, 1987.
	C4	Cazenave, "Idiotypic-anti-idiotypic regulation of antibody synthesis in rabbits," <i>Proc. Natl. Acad. Sci. USA</i> , 74:5122-5125, 1977.
	C5	Chirgwin, <i>et al.</i> , "Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease," <i>Biochemistry</i> 18:5294-5299, 1979.
	C6	Chomczynski and Sacchi, "Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction," <i>Anal. Biochem.</i> 162:156-159, 1987.
	C7	Chomczynski, "Solubilization in formamide protects RNA from degradation," <i>Nucleic Acids Res.</i> 20:3791-3792, 1992.
	C8	Coburn and Mackie, "Overexpression, purification, and properties of Escherichia coli ribonuclease II," <i>J. Biol. Chem.</i> 271:1048-1053, 1996.
	C9	Gilleland and Hockett Jr., "Stability of RNA molecules stored in gitc," <i>Biotechniques</i> 25:944-948, 1998.

25462392.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. AMBI:089US	Serial No. 10/786,875
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Gary J. Latham <i>et al.</i>	
	Filing Date: February 25, 2004	Group: 1634
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Jocoli and Ronald, "Inhibition of ribonuclease activity by bentonite," <i>Can. J. Biochem.</i> 51:1558-1565, 1973.
	C11	Jones, "On the efficacy of commonly used ribonuclease inhibitors," <i>Biochem. Biophys. Res. Commun.</i> 69:469-474, 1976.
	C12	Lee <i>et al.</i> , "The use of immobilized anti-ribonuclease antibodies in the isolation of polyribosomes," <i>Immunochemistry</i> , 9:210-213, 1972.
	C13	Lin, "Inactivation of pancreatic ribonuclease with hydroxylamine-oxygen-cupric ion," <i>Biochim. et Biophys. Acta</i> 263:680-682, 1972.
	C14	Mendelsohn and Young, "Efficacy of sodium dodecyl sulfate, diethyl pyrocarbonate, proteinase k and heparin using a sensitive ribonuclease assay," <i>Biochim. et Biophys. Acta</i> 519:461-473, 1978.
	C15	Murphy <i>et al.</i> , "A potent, cost-effective RNase inhibitor," <i>Biotechniques</i> 18:1068-1073, 1995.
	C16	O'Leary, "Reducing the Impact of Endogenous Ribonucleases on Reverse Transcription-PCR Assay Systems," <i>Clinical Chemistry</i> , 45(4):449-450, 1999.
	C17	Pelham and Jackson, "An efficient mRNA dependent translation system for reticulocyte lysates," <i>Eur. J. Biochem.</i> 67:247-256, 1976.
	C18	Russo and Shapiro, "Potent inhibition of mammalian ribonucleases by 3' 5'-pyrophosphate-linked nucleotides," <i>J. Biol. Chem.</i> 274:14,902-14,908, 1999.
	C19	Sambrook, et al., "Molecular cloning, a laboratory manual," pp. 7.16-7.52, 1989.
	C20	Spackman <i>et al.</i> , "The Disulfide Bonds of Ribonuclease," <i>J. Biol. Chem.</i> 235:648-659, 1960.
	C21	Spickler and Mackie, "Action of RNase ii and polynucleotide phosphorylase against RNase containing stem-loops of defined structure," <i>J. Bacteriology</i> 182(9): 2422-2427, 2000.
	C22	Trent <i>et al.</i> , "A comparison of new world alphaviruses in the western equine encephalomyelitis complex by immunochemical and oligonucleotide fingerprint techniques," <i>J. Gen. Virol.</i> , 47:261-282, 1980.
	C23	Wolf <i>et al.</i> , "A mechanism of the irreversible inactivation of bovine pancreatic ribonuclease by diethylpyrocarbonate," <i>Eur. J. Biochem.</i> 13:519-525, 1970.
	C24	Wu, <i>et al.</i> , "Methods in Gene Biotechnology," CRC Press, Boca Raton, FL, pp. 29-56, 1997.

25462392.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified) List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Atty. Docket No. AMBI:089US	Serial No. 10/786,875
	Applicant Gary J. Latham <i>et al.</i>	
	Filing Date: February 25, 2004	Group: 1634
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C25	Zale and Klibanov, "Why does ribonuclease irreversibly inactivate at high temperatures?," <i>Biochemistry</i> 25:5432-5444, 1986.
	C26	Provisional Application Number 60/547,721 filed February 25, 2004.
	C27	Co-Pending U.S. Patent Application Number 10/675,860 filed September 30, 2003.

25462392.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.